Can ozanimod cure ulcerative colitis?

Ozamod (ozanimod) is the first sphingosine-1-phosphate receptor (S1PR) modulator approved in the United States for the treatment of adults with moderately to severely active ulcerative colitis. The oral formulation of ozanimod is administered once daily as induction and maintenance therapy. Intwo clinical trials, ozanimod was effective in inducing and maintaining clinical remission in adults with moderately to severely active ulcerative colitis. It was generally well tolerated, with manageable or transient adverse events (AEs). Current data from two clinical trials are consistent with preliminary studies on efficacy and tolerability, and no new safety signals were observed. While further data will be beneficial, ozanimod expands treatment options for adults with moderately to severely active ulcerative colitis.